¼¼°èÀÇ ÇǺÎÁø±ÕÁõ ½ÃÀå º¸°í¼­(2025³â)
Dermatomycoses Global Market Report 2025
»óǰÄÚµå : 1730826
¸®¼­Ä¡»ç : The Business Research Company
¹ßÇàÀÏ : On Demand Report
ÆäÀÌÁö Á¤º¸ : ¿µ¹® 175 Pages
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,490 £Ü 6,183,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 6,490 £Ü 8,938,000
PDF (Site License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷ÀåÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 8,490 £Ü 11,692,000
PDF (Enterprise License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.
¤± º¸°í¼­¿¡ µû¶ó ÃֽŠÁ¤º¸·Î ¾÷µ¥ÀÌÆ®ÇÏ¿© º¸³»µå¸³´Ï´Ù. ¹è¼Û±âÀÏÀº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

ÇǺÎÁø±ÕÁõ ½ÃÀå ±Ô¸ð´Â ÇâÈÄ ¼ö³â°£ °­·ÂÇÑ ¼ºÀåÀÌ ¿¹»óµË´Ï´Ù. 2029³â¿¡´Â CAGR 5.6%·Î ¼ºÀåÇÒ Àü¸ÁÀ̸ç, 185¾ï 9,000¸¸ ´Þ·¯·Î ¼ºÀåÀÌ ¿¹ÃøµË´Ï´Ù. ¿¹Ãø ±â°£ µ¿¾È ¿¹»óµÇ´Â ¼ºÀåÀÇ ¿øµ¿·ÂÀº °í·ÉÈ­ Àα¸ Áõ°¡, ¾à¹° ³»¼º Áø±Õ Áõ°¡, õ¿¬ ¹× À¯±â Ç×Áø±Õ Á¦Ç°¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡, »ý¸í°øÇÐ ¹× Ç×Áø±Õ ¿¬±¸ÀÇ Áøº¸, °³¹ßµµ»ó Áö¿ª¿¡¼­ ÇコÄɾî Á¢±Ù °³¼± µîÀÇ ¿äÀÎÀÔ´Ï´Ù. ÀÌ ±â°£¿¡ ¿¹»óµÇ´Â ÁÖ¿ä µ¿ÇâÀ¸·Î´Â »õ·Î¿î Ç×Áø±ÕÁ¦ °³¹ß, ½Å¼Ó Áø´Ü¹ýÀÇ Áøº¸, ÇǺΰúÇÐÀÇ ÀΰøÁö´É ÅëÇÕ, ³ª³ë±â¼úÀ» ÀÌ¿ëÇÑ Ç×Áø±Õ Ä¡·á¹ýÀÇ ¹ßÀü, ¹Ì»ý¹° ±â¹Ý Ä¡·á¹ýÀÇ Çõ½Å µîÀÌ ÀÖ½À´Ï´Ù.

Áø±Õ °¨¿°ÀÇ À¯º´·ü Áõ°¡´Â ÇâÈÄ ¼ö³â°£ ÇǺÎÁø±ÕÁõ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. Áø±Õ °¨¿°Àº Áø±ÕÀÌ ÇǺÎ, ¼ÕÅé, ¸ð¹ß, ³»Àå µî¿¡ °¨¿°µÊÀ¸·Î½á ¹ßº´ÇÏ¸ç ´Ù¾çÇÑ °Ç°­ ÇÕº´ÁõÀ» ÀÏÀ¸Åµ´Ï´Ù. ±¤¿ªÇ×»ýÁ¦ °ú´Ù »ç¿ëÀº ÀÚ¿¬ ¸¶ÀÌÅ©·Î¹ÙÀÌ¿ÈÀ» ÆÄ±«Çϰí Áø±ÕÀÌ ¹ø½ÄÇØ °¨¿°º´À» ÀÏÀ¸Å°´Â ȯ°æÀ» ¸¸µé¾î ³À´Ï´Ù. ÀÌ·¯ÇÑ È¥¶õÀº ½ÅüÀÇ ÀÚ¿¬½º·¯¿î ¹æ¾î ±â±¸¸¦ ¾àÈ­½ÃÄÑ ±âȸ±Õ °¨¿°¿¡ °É¸®±â ½±°Ô ÇÕ´Ï´Ù. ÇǺÎÁø±ÕÁõ ÇǺλç»ó±Õ, È¿¸ð, °õÆÎÀÌ¿¡ ÀÇÇØ ¾ß±âµÇ´Â Áø±ÕÁõÀº ´Ù¾çÇÑ Á¶Á÷¿¡ ¿µÇâÀ» ¹ÌÃÄ Ç¥¸é °¨¿°°ú Àü½Å °¨¿°À» ¸ðµÎ ÀÏÀ¸Åµ´Ï´Ù. ¿¹¸¦ µé¾î 2023³â 11¿ù ¿µ±¹ °øÁߺ¸°Ç±â±¸ÀÎ UK Health Security Agency´Â Àü ¼¼°è ÃßÁ¤À¸·Î´Â ¿¬°£ 650¸¸ ¸íÀÇ Ä§½À¼º Áø±Õ °¨¿°º´ÀÌ ¹ß»ýÇØ ¾à 380¸¸ ¸íÀÌ »ç¸ÁÇϰí 250¸¸ ¸íÀÌ ÀÌµé °¨¿°º´¿¡ Á÷Á¢ ±âÀÎÇϰí ÀÖ´Ù°í º¸°íÇß½À´Ï´Ù. ±× °á°ú Áø±Õ °¨¿°ÁõÀÇ À¯º´·ü »ó½ÂÀÌ ÇǺΠÁø±ÕÁõ ½ÃÀåÀÇ ¼ºÀåÀ» ÃËÁøÇϰí ÀÖ½À´Ï´Ù.

°æ±¸¾à¿¡ ´ëÇÑ ¼ö¿ä Áõ°¡°¡ ÇâÈÄ ÇǺÎÁø±ÕÁõ ½ÃÀåÀÇ È®´ë¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ¿¹ÃøµÇ°í ÀÖ½À´Ï´Ù. °æ±¸¾àÀ̶õ ¾Ë¾à, ĸ½¶Á¦, ¾×Á¦ µîÀÇ ÇüÅ·ΠÀÔÀ¸·Î º¹¿ëÇÏ´Â ¾àÁ¦¸¦ ¸»ÇÏ¸ç ¼ÒÈ­±â°ü¿¡¼­ Èí¼öµË´Ï´Ù. Áֻ糪 ´Ù¸¥ ¹è´Þ ¹æ¹ý¿¡ ºñÇØ ÆíÀǼºÀÌ ³ô°í È¿°úµµ ³ô±â ¶§¹®¿¡ °æ±¸¾àÀÌ ´Ù¾çÇÑ ÁúȯÀÇ Ä¡·á ¼±ÅÃÁö·Î ¼±È£µÇ°í ÀÖ½À´Ï´Ù. ÇǺÎÁø±ÕÁõ Ä¡·áÀÇ ÀåÁ¡Àº Àü½Å¼º Ç×Áø±ÕÁ¦°¡ Ç÷¾×¼øÈ¯À» ÅëÇØ °¨¿°µÈ ÇǺÎ, ¸ð¹ß, ¼ÕÅé¿¡ ħÅõÇØ ¿Ü¿ë¾à¿¡ ºñÇØ ´õ ±í°í ´õ ¿À·¡ Ä¡·á°¡ Áö¼ÓµÈ´Ù´Â °ÍÀÔ´Ï´Ù. ¿¹¸¦ µé¾î, 2022³â 10¿ù ¹Ì±¹ÀÇ Á¤ºÎ±â°üÀÎ Áúº´´ëÃ¥¿¹¹æ¼¾ÅÍ´Â °æ±¸Ç×¹ÙÀÌ·¯½ºÁ¦ Á¶Á¦ ¼ö°¡ 57% Áõ°¡ÇÏ¿© 2022³â 4¿ù 24ÀϺÎÅÍ 5¿ù 21ÀÏ »çÀÌ¿¡ 10¸¸ ¸í´ç 643¸íÀ̾ú´ø °ÍÀÌ 2022³â 7¿ù 31ÀϺÎÅÍ 8¿ù 28ÀÏ »çÀÌ¿¡ 10¸¸ ¸í´ç 1,012¸íÀ¸·Î Áõ°¡ÇÏ¿´´Ù°í º¸°íÇϰí ÀÖ½À´Ï´Ù. ±× °á°ú °æ±¸¾à¿¡ ´ëÇÑ ¼ö¿äÀÇ Áõ°¡°¡ ÇǺΠÁø±ÕÁõ ½ÃÀåÀ» °ßÀÎÇϰí ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå ÁÖ¿ä ¿ä¾à

Á¦2Àå ½ÃÀå Æ¯Â¡

Á¦3Àå ½ÃÀå µ¿Çâ ¹× Àü·«

Á¦4Àå ½ÃÀå-°Å½Ã°æÁ¦ ½Ã³ª¸®¿À ±Ý¸®, ÀÎÇ÷¹À̼Ç, ÁöÁ¤ÇÐ, ½ÅÇü Äڷγª ¹ÙÀÌ·¯½º °¨¿°ÀÇ ¿µÇâ°ú ȸº¹ÀÌ ½ÃÀå¿¡ ¹ÌÄ¡´Â ¿µÇâÀ» Æ÷ÇÔÇÑ °Å½Ã°æÁ¦ ½Ã³ª¸®¿À

Á¦5Àå ¼¼°èÀÇ ¼ºÀå ºÐ¼® ¹× Àü·« ºÐ¼® ÇÁ·¹ÀÓ¿öÅ©

Á¦6Àå ½ÃÀå ¼¼ºÐÈ­

Á¦7Àå Áö¿ªº° ¹× ±¹°¡º° ºÐ¼®

Á¦8Àå ¾Æ½Ã¾ÆÅÂÆò¾ç ½ÃÀå

Á¦9Àå Áß±¹ ½ÃÀå

Á¦10Àå Àεµ ½ÃÀå

Á¦11Àå ÀϺ» ½ÃÀå

Á¦12Àå È£ÁÖ ½ÃÀå

Á¦13Àå Àεµ³×½Ã¾Æ ½ÃÀå

Á¦14Àå Çѱ¹ ½ÃÀå

Á¦15Àå ¼­À¯·´ ½ÃÀå

Á¦16Àå ¿µ±¹ ½ÃÀå

Á¦17Àå µ¶ÀÏ ½ÃÀå

Á¦18Àå ÇÁ¶û½º ½ÃÀå

Á¦19Àå ÀÌÅ»¸®¾Æ ½ÃÀå

Á¦20Àå ½ºÆäÀÎ ½ÃÀå

Á¦21Àå µ¿À¯·´ ½ÃÀå

Á¦22Àå ·¯½Ã¾Æ ½ÃÀå

Á¦23Àå ºÏ¹Ì ½ÃÀå

Á¦24Àå ¹Ì±¹ ½ÃÀå

Á¦25Àå ij³ª´Ù ½ÃÀå

Á¦26Àå ³²¹Ì ½ÃÀå

Á¦27Àå ºê¶óÁú ½ÃÀå

Á¦28Àå Áßµ¿ ½ÃÀå

Á¦29Àå ¾ÆÇÁ¸®Ä« ½ÃÀå

Á¦30Àå °æÀï ±¸µµ ¹× ±â¾÷ ÇÁ·ÎÆÄÀÏ

Á¦31Àå ±âŸ ÁÖ¿ä ±â¾÷ ¹× Çõ½Å ±â¾÷

Á¦32Àå ¼¼°è ½ÃÀå °æÀï º¥Ä¡¸¶Å· ¹× ´ë½Ãº¸µå

Á¦33Àå ÁÖ¿ä ÀμöÇÕº´(M&A)

Á¦34Àå ÃÖ±Ù ½ÃÀå µ¿Çâ

Á¦35Àå ½ÃÀåÀÇ ÀáÀç·ÂÀÌ ³ôÀº ±¹°¡, ºÎ¹® ¹× Àü·«

Á¦36Àå ºÎ·Ï

AJY
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Dermatomycoses refer to a group of fungal infections that affect the skin, hair, and nails, primarily caused by dermatophytes, yeasts, or molds. These infections often result in symptoms such as itching, scaling, redness, and skin inflammation, negatively impacting skin health. The primary aim of treatment is to eradicate the fungal infection, relieve symptoms, and prevent recurrence through the use of antifungal medications, proper hygiene, and consistent skin care practices.

The main drug categories for treating dermatomycoses include corticosteroids, corticosteroid-sparing agents, immunosuppressives, immunomodulators, antifungals, and others. Corticosteroids are anti-inflammatory drugs that help reduce swelling, redness, and itching in skin conditions. These medications can be administered in various forms, such as oral, parenteral, topical, and others, and are used by different end-users, including hospitals, specialty clinics, and others.

The dermatomycoses market research report is one of a series of new reports from The Business Research Company that provides dermatomycoses market statistics, including the dermatomycoses industry global market size, regional shares, competitors with the dermatomycoses market share, detailed dermatomycoses market segments, market trends, and opportunities, and any further data you may need to thrive in the dermatomycoses industry. This dermatomycoses market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dermatomycoses market size has grown strongly in recent years. It will grow from $14.12 billion in 2024 to $14.95 billion in 2025 at a compound annual growth rate (CAGR) of 5.9%. The growth during the historic period can be attributed to advancements in antifungal therapies, the rising prevalence of fungal infections, growing awareness about skin health, improvements in diagnostic techniques, and the expansion of over-the-counter antifungal products.

The dermatomycoses market size is expected to see strong growth in the next few years. It will grow to $18.59 billion in 2029 at a compound annual growth rate (CAGR) of 5.6%. The anticipated growth during the forecast period is driven by factors such as the rising aging population, the increasing prevalence of drug-resistant fungal strains, the growing demand for natural and organic antifungal products, advancements in biotechnology and antifungal research, and improved healthcare access in developing regions. Key trends expected in this period include the development of new antifungal drugs, progress in rapid diagnostic methods, the integration of artificial intelligence in dermatology, advancements in nanotechnology-based antifungal treatments, and innovations in microbiome-based therapies.

The increasing prevalence of fungal infections is expected to drive the growth of the dermatomycoses market in the coming years. Fungal infections occur when fungi infect the skin, nails, hair, or internal organs, leading to various health complications. The excessive use of broad-spectrum antibiotics disrupts the natural microbiome, creating an environment that allows fungi to thrive and cause infections. This disruption weakens the body's natural defense mechanisms, making individuals more susceptible to opportunistic fungal infections. Dermatomycoses, caused by dermatophytes, yeasts, and molds, are responsible for fungal diseases, affecting different tissues and leading to both superficial and systemic infections. For example, in November 2023, the UK Health Security Agency, a UK-based public health organization, reported that global estimates indicate an annual occurrence of 6.5 million invasive fungal infections, resulting in approximately 3.8 million deaths, with 2.5 million directly attributed to these infections. As a result, the rising prevalence of fungal infections is fueling the growth of the dermatomycoses market.

The increasing demand for oral drugs is anticipated to contribute to the expansion of the dermatomycoses market in the future. Oral drugs are medications taken by mouth in the form of tablets, capsules, or liquids, which are absorbed through the digestive system. The preference for oral drugs is growing as they offer greater convenience and effectiveness compared to injections or other delivery methods, making them a favored treatment option for various conditions. Dermatomycoses treatment benefits from oral drugs by enabling systemic antifungal agents to penetrate infected skin, hair, or nails through blood circulation, ensuring deeper and longer-lasting treatment compared to topical applications. For example, in October 2022, the Centers for Disease Control and Prevention, a US-based government agency, reported a 57% increase in oral antiviral dispensing, rising from 643 per 100,000 persons between April 24 and May 21, 2022, to 1,012 per 100,000 persons between July 31 and August 28, 2022. Consequently, the growing demand for oral drugs is driving the dermatomycoses market forward.

Leading companies in the dermatomycoses market are concentrating on investigational new drug candidates to enhance onychomycosis treatment and improve therapeutic efficacy. An investigational new drug (IND) candidate is a pharmaceutical compound undergoing preclinical or clinical trials to assess its safety, effectiveness, and potential for regulatory approval before becoming an authorized treatment. For instance, in January 2024, Vanda Pharmaceuticals Inc., a US-based biopharmaceutical company, received approval from the US Food and Drug Administration (FDA) for its investigational new drug VTR-297, intended for the treatment of onychomycosis. VTR-297 is distinguished by its histone deacetylase (HDAC) inhibitor properties, setting it apart from conventional antifungal treatments. This approach targets the root cause of fungal growth, exhibiting strong antifungal activity against dermatophytes and other fungi. The novel mechanism of action has the potential to deliver faster and more effective treatment outcomes while reducing the risk of infection recurrence, addressing a critical unmet need in onychomycosis treatment.

Major players in the dermatomycoses market are Pfizer Inc., Bayer AG, Saphnix Life Sciences, MITS Healthcare Private Limited, Weefsel Pharma, AdvaCare Pharma, Associated Biotech, Healthy Life Pharma Private Limited, Blueberry Therapeutics Ltd., Livealth Biopharma Pvt. Ltd., LGM Pharma, SiNi Pharma Pvt. Ltd., Joshi Agrochem Pharma Private Limited, Wellona Pharma, Abiba Pharmacia Pvt. Ltd., Vee Excel Drugs & Pharmaceuticals Pvt. Ltd., Femcorp Pharma, Lexicare Pharma Pvt. Ltd., Glamris Dermacare, Henin Lukinz.

North America was the largest region in the dermatomycoses market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dermatomycoses report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dermatomycoses market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dermatomycoses market consists of sales of barrier creams or protective skin creams, medicated soaps and body washes, and cryotherapy products. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dermatomycoses Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dermatomycoses market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for dermatomycoses ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dermatomycoses market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Dermatomycoses Market Characteristics

3. Dermatomycoses Market Trends And Strategies

4. Dermatomycoses Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Dermatomycoses Growth Analysis And Strategic Analysis Framework

6. Dermatomycoses Market Segmentation

7. Dermatomycoses Market Regional And Country Analysis

8. Asia-Pacific Dermatomycoses Market

9. China Dermatomycoses Market

10. India Dermatomycoses Market

11. Japan Dermatomycoses Market

12. Australia Dermatomycoses Market

13. Indonesia Dermatomycoses Market

14. South Korea Dermatomycoses Market

15. Western Europe Dermatomycoses Market

16. UK Dermatomycoses Market

17. Germany Dermatomycoses Market

18. France Dermatomycoses Market

19. Italy Dermatomycoses Market

20. Spain Dermatomycoses Market

21. Eastern Europe Dermatomycoses Market

22. Russia Dermatomycoses Market

23. North America Dermatomycoses Market

24. USA Dermatomycoses Market

25. Canada Dermatomycoses Market

26. South America Dermatomycoses Market

27. Brazil Dermatomycoses Market

28. Middle East Dermatomycoses Market

29. Africa Dermatomycoses Market

30. Dermatomycoses Market Competitive Landscape And Company Profiles

31. Dermatomycoses Market Other Major And Innovative Companies

32. Global Dermatomycoses Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dermatomycoses Market

34. Recent Developments In The Dermatomycoses Market

35. Dermatomycoses Market High Potential Countries, Segments and Strategies

36. Appendix

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â